Annals of Internal Medicine最新文献

筛选
英文 中文
Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals : A Retrospective Cohort Study. 评估美国医院临床医生使用新一代抗生素治疗耐药革兰氏阴性菌感染的情况 :回顾性队列研究。
Annals of Internal Medicine Pub Date : 2024-04-19 DOI: 10.7326/M23-2309
J. Strich, Ahmed Mishuk, Gouqing Diao, Alexander Lawandi, Willy Li, C. Demirkale, A. Babiker, A. Mancera, Bruce J Swihart, Morgan Walker, C. Yek, Maniraj Neupane, Nathaniel De Jonge, S. Warner, S. Kadri
{"title":"Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals : A Retrospective Cohort Study.","authors":"J. Strich, Ahmed Mishuk, Gouqing Diao, Alexander Lawandi, Willy Li, C. Demirkale, A. Babiker, A. Mancera, Bruce J Swihart, Morgan Walker, C. Yek, Maniraj Neupane, Nathaniel De Jonge, S. Warner, S. Kadri","doi":"10.7326/M23-2309","DOIUrl":"https://doi.org/10.7326/M23-2309","url":null,"abstract":"BACKGROUND\u0000The U.S. antibiotic market failure has threatened future innovation and supply. Understanding when and why clinicians underutilize recently approved gram-negative antibiotics might help prioritize the patient in future antibiotic development and potential market entry rewards.\u0000\u0000\u0000OBJECTIVE\u0000To determine use patterns of recently U.S. Food and Drug Administration (FDA)-approved gram-negative antibiotics (ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, plazomicin, eravacycline, imipenem-relebactam-cilastatin, and cefiderocol) and identify factors associated with their preferential use (over traditional generic agents) in patients with gram-negative infections due to pathogens displaying difficult-to-treat resistance (DTR; that is, resistance to all first-line antibiotics).\u0000\u0000\u0000DESIGN\u0000Retrospective cohort.\u0000\u0000\u0000SETTING\u0000619 U.S. hospitals.\u0000\u0000\u0000PARTICIPANTS\u0000Adult inpatients.\u0000\u0000\u0000MEASUREMENTS\u0000Quarterly percentage change in antibiotic use was calculated using weighted linear regression. Machine learning selected candidate variables, and mixed models identified factors associated with new (vs. traditional) antibiotic use in DTR infections.\u0000\u0000\u0000RESULTS\u0000Between quarter 1 of 2016 and quarter 2 of 2021, ceftolozane-tazobactam (approved 2014) and ceftazidime-avibactam (2015) predominated new antibiotic usage whereas subsequently approved gram-negative antibiotics saw relatively sluggish uptake. Among gram-negative infection hospitalizations, 0.7% (2551 [2631 episodes] of 362 142) displayed DTR pathogens. Patients were treated exclusively using traditional agents in 1091 of 2631 DTR episodes (41.5%), including \"reserve\" antibiotics such as polymyxins, aminoglycosides, and tigecycline in 865 of 1091 episodes (79.3%). Patients with bacteremia and chronic diseases had greater adjusted probabilities and those with do-not-resuscitate status, acute liver failure, and Acinetobacter baumannii complex and other nonpseudomonal nonfermenter pathogens had lower adjusted probabilities of receiving newer (vs. traditional) antibiotics for DTR infections, respectively. Availability of susceptibility testing for new antibiotics increased probability of usage.\u0000\u0000\u0000LIMITATION\u0000Residual confounding.\u0000\u0000\u0000CONCLUSION\u0000Despite FDA approval of 7 next-generation gram-negative antibiotics between 2014 and 2019, clinicians still frequently treat resistant gram-negative infections with older, generic antibiotics with suboptimal safety-efficacy profiles. Future antibiotics with innovative mechanisms targeting untapped pathogen niches, widely available susceptibility testing, and evidence demonstrating improved outcomes in resistant infections might enhance utilization.\u0000\u0000\u0000PRIMARY FUNDING SOURCE\u0000U.S. Food and Drug Administration; NIH Intramural Research Program.","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":" 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140683634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians. 成人 2 型糖尿病患者接受新型药物治疗的成本效益:为美国内科医师学会撰写的《成本效益研究系统回顾》(A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians)。
Annals of Internal Medicine Pub Date : 2024-04-19 DOI: 10.7326/M23-1492
J. Schousboe, Adrienne Landsteiner, Tyler Drake, Shahnaz Sultan, L. Langsetmo, Anjum S. Kaka, Maylen Anthony, Charles J Billington, Caleb Kalinowski, Kristen E Ullman, Timothy J Wilt
{"title":"Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians.","authors":"J. Schousboe, Adrienne Landsteiner, Tyler Drake, Shahnaz Sultan, L. Langsetmo, Anjum S. Kaka, Maylen Anthony, Charles J Billington, Caleb Kalinowski, Kristen E Ullman, Timothy J Wilt","doi":"10.7326/M23-1492","DOIUrl":"https://doi.org/10.7326/M23-1492","url":null,"abstract":"BACKGROUND\u0000In the United States, costs of antidiabetes medications exceed $327 billion.\u0000\u0000\u0000PURPOSE\u0000To systematically review cost-effectiveness analyses (CEAs) of newer antidiabetes medications for type 2 diabetes.\u0000\u0000\u0000DATA SOURCES\u0000Bibliographic databases from 1 January 2010 through 13 July 2023, limited to English.\u0000\u0000\u0000STUDY SELECTION\u0000Nonindustry-funded CEAs, done from a U.S. perspective that estimated cost per quality-adjusted life-year (QALY) gained for newer antidiabetic medications. Two reviewers screened the literature; disagreements were resolved with a third reviewer.\u0000\u0000\u0000DATA EXTRACTION\u0000Cost-effectiveness analyses were reviewed for treatment comparisons, model inputs, and outcomes. Risk of bias (RoB) of the CEAs was assessed using Drummond criteria and certainty of evidence (CoE) was assessed using GRADE (Grading of Recommendations Assessment, Development, and Evaluations). Certainty of evidence was determined using cost per QALY thresholds predetermined by the American College of Physicians Clinical Guidelines Committee; low (>$150 000), intermediate ($50 to $150 000), or high (<$50 000) value per QALY compared with the alternative.\u0000\u0000\u0000DATA SYNTHESIS\u0000Nine CEAs were eligible (2 low, 1 high, and 6 some concerns RoB), evaluating glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucose-dependent insulinotropic peptide agonist (GIP/GLP1a), and insulin. Comparators were metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and others. Compared with metformin, GLP1a and SGLT2i are low value as first-line therapy (high CoE) but may be of intermediate value when added to metformin or background therapy compared with adding nothing (low CoE). Insulin analogues may be similarly effective but more expensive than NPH insulin (low CoE). The GIP/GLP1a value is uncertain (insufficient CoE).\u0000\u0000\u0000LIMITATIONS\u0000Cost-effectiveness analyses varied in methodological approach, assumptions, and drug comparisons. Risk of bias and GRADE method for CEAs are not well established.\u0000\u0000\u0000CONCLUSION\u0000Glucagon-like peptide-1 agonists and SGLT2i are of low value as first-line therapy but may be of intermediate value when added to metformin or other background therapy compared with adding nothing. Other drugs and comparisons are of low or uncertain value. Results are sensitive to drug effectiveness and cost assumptions.\u0000\u0000\u0000PRIMARY FUNDING SOURCE\u0000American College of Physicians. (PROSPERO: CRD42022382315).","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":" 26","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140684875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Visual Guideline - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Visual Clinical Guideline From the American College of Physicians. 可视化指南 - 2 型糖尿病成人患者的新型药物治疗:美国内科医师学会的可视化临床指南。
Annals of Internal Medicine Pub Date : 2024-04-19 DOI: 10.7326/M24-0803
{"title":"Visual Guideline - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Visual Clinical Guideline From the American College of Physicians.","authors":"","doi":"10.7326/M24-0803","DOIUrl":"https://doi.org/10.7326/M24-0803","url":null,"abstract":"The purpose of this visual clinical guideline is to provide a visual summary of ACP's clinical guideline, \"Newer Pharmacologic Treatments in Adults With Type 2 Diabetes.\" In addition, this visual clinical guideline features an interactive data visualization of findings associated with ACP's clinical recommendations for this topic.","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":" 46","pages":"eM240803"},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140683780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiology: What You May Have Missed in 2023. 心脏病学您可能错过的 2023 年。
Annals of Internal Medicine Pub Date : 2024-04-16 DOI: 10.7326/M24-0581
Abdulrahman Alfraih, Achieng Tago, Michael Lacombe, William G Kussmaul
{"title":"Cardiology: What You May Have Missed in 2023.","authors":"Abdulrahman Alfraih, Achieng Tago, Michael Lacombe, William G Kussmaul","doi":"10.7326/M24-0581","DOIUrl":"https://doi.org/10.7326/M24-0581","url":null,"abstract":"Cardiology and all its subspecialties continue to push the envelope in developing new treatment strategies for a wide variety of diseases. After screening more than 1300 articles, we highlight a selection of important cardiology articles published in 2023. Starting with prevention, we note articles that look at the effect of semaglutide in patients with obesity as well as a first-in-class drug, bempedoic acid, on cardiovascular outcomes. We have also examined new evidence comparing conservative management with invasive management of frail, older patients with non-ST-segment elevation myocardial infarction (NSTEMI). In patients with cardiac arrest secondary to NSTEMI, another article examines the rationale for expedited transfer to a cardiac arrest center. The STREAM-2 (Strategic Reperfusion in Elderly Patients Early After Myocardial Infarction) trial builds on looking at half-dose thrombolysis in older populations with STEMI. Emphasis is placed on guideline-directed medical therapy before hospital discharge in those with heart failure. In addition, in patients with stable symptomatic coronary artery disease, initial noninvasive testing using coronary computed tomography angiography may be a viable option compared with invasive strategies. More details have emerged on anticoagulation strategies in those with device-detected atrial fibrillation. Finally, transcatheter approaches to treat both mitral and tricuspid regurgitation have also been included.","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":"7 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140697586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Reducing Care Overuse in Older Patients Using Professional Norms and Accountability. 更正:利用专业规范和问责制减少老年患者过度使用护理服务。
Annals of Internal Medicine Pub Date : 2024-04-16 DOI: 10.7326/L24-0117
{"title":"Correction: Reducing Care Overuse in Older Patients Using Professional Norms and Accountability.","authors":"","doi":"10.7326/L24-0117","DOIUrl":"https://doi.org/10.7326/L24-0117","url":null,"abstract":"","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":"22 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140697482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Critical Care: What You May Have Missed in 2023. 重症监护:您可能错过的 2023 年。
Annals of Internal Medicine Pub Date : 2024-04-16 DOI: 10.7326/M24-0565
H. Ajzenberg, M. Binhashr, M. Hewitt, Michael Unger
{"title":"Critical Care: What You May Have Missed in 2023.","authors":"H. Ajzenberg, M. Binhashr, M. Hewitt, Michael Unger","doi":"10.7326/M24-0565","DOIUrl":"https://doi.org/10.7326/M24-0565","url":null,"abstract":"Critical care medicine is a specialty that brings together a truly wide spectrum of patient populations, disease states, and treatment methods. This article highlights 10 important pieces of research from 2023 (and 1 from 2022) in critical care. The literature was screened for new evidence relevant to internal medicine physicians and hospitalists whose focus of practice is not critical care but who may be taking care of seriously ill patients. The articles highlight the diverse spectrum of pathology and interplay of various specialties that go into critical care. Topics include transfusion medicine, fluid resuscitation, safe intubation practices and respiratory failure, and the management of acute ischemic stroke. Several trials are groundbreaking, forcing clinicians to reconsider preexisting dogma and likely adopt new treatment strategies.","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":"83 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140695776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastroenterology/Hepatology: What You May Have Missed in 2023. 胃肠病学/肝病学:您可能错过的 2023 年。
Annals of Internal Medicine Pub Date : 2024-04-16 DOI: 10.7326/M24-0505
Sama Anvari, Kayla Dadgar, C. Galts, Michael Bretthauer
{"title":"Gastroenterology/Hepatology: What You May Have Missed in 2023.","authors":"Sama Anvari, Kayla Dadgar, C. Galts, Michael Bretthauer","doi":"10.7326/M24-0505","DOIUrl":"https://doi.org/10.7326/M24-0505","url":null,"abstract":"This article summarizes clinically important gastroenterology developments from 2023 for internal medicine specialists. In colorectal cancer screening, a new RNA fecal screening test is on the horizon, as well as a new analysis on the benefits of using artificial intelligence in screening colonoscopy to detect more polyps. There is new evidence for management of gastrointestinal bleeding, a new drug for treatment of recurrent small-intestinal angiodysplasia, and a new endoscopic treatment method in patients with gastrointestinal tumor bleeding. The authors feature a randomized trial about amitriptyline as treatment for patients with irritable bowel syndrome by primary care providers and bring you news about new biologic agents for inflammatory bowel disease and eosinophilic esophagitis. Finally, they review 2 important articles on new terminology and management of metabolic dysfunction-associated fatty liver disease.","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140694935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rheumatology: What You May Have Missed in 2023. 风湿病学您可能错过的 2023 年。
Annals of Internal Medicine Pub Date : 2024-04-16 DOI: 10.7326/M24-0678
Kafaf Jalali, L. A. Mandl
{"title":"Rheumatology: What You May Have Missed in 2023.","authors":"Kafaf Jalali, L. A. Mandl","doi":"10.7326/M24-0678","DOIUrl":"https://doi.org/10.7326/M24-0678","url":null,"abstract":"Many patients with rheumatologic conditions receive care from physicians other than rheumatologists. Here we note key findings from 6 studies in rheumatology published in 2023 that offer valuable insights for internal medicine specialists and subspecialists outside of rheumatology. The first study investigated the effect of low-dose glucocorticoids on patients with rheumatoid arthritis (RA) over 2 years and challenged existing perceptions about the risks of glucocorticoids in this setting. The second study focused on the updated guideline for preventing and treating glucocorticoid-induced osteoporosis. With the chronic and widespread use of glucocorticoids, the American College of Rheumatology emphasized the importance of assessing fracture risk and initiating pharmacologic therapy when appropriate. The third study explored the potential use of methotrexate in treating inflammatory hand osteoarthritis, suggesting a novel approach to managing this challenging and common condition. The results of the fourth article we highlight suggest that sarilumab has promise as an adjunct treatment of polymyalgia rheumatica relapse during glucocorticoid dosage tapering. The fifth study evaluated sublingual cyclobenzaprine for fibromyalgia treatment, noting both potential benefits and risks. Finally, the sixth article is a systematic review and meta-analysis that assessed the therapeutic equivalence of biosimilars and reference biologics in the treatment of patients with RA. Knowledge of this recent literature will be useful to clinicians regardless of specialty who care for patients with these commonly encountered conditions.","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140695392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncology: What You May Have Missed in 2023. 肿瘤学您可能错过的 2023 年。
Annals of Internal Medicine Pub Date : 2024-04-16 DOI: 10.7326/M24-0520
Courtney H Coschi, Lorin Dodbiba, DuPont Guerry
{"title":"Oncology: What You May Have Missed in 2023.","authors":"Courtney H Coschi, Lorin Dodbiba, DuPont Guerry","doi":"10.7326/M24-0520","DOIUrl":"https://doi.org/10.7326/M24-0520","url":null,"abstract":"Advances in oncology treatment methods have improved outcomes and quality of life for patients with cancer. However, care of these patients can be complex, and the contribution of physicians from different specialties is crucial. This article highlights important publications from 2023 on topics across a wide spectrum relating to the management of oncology patients. The literature was screened for significant new evidence that is relevant to internal medicine specialists and subspecialists whose focus is not oncology. Two articles address the importance of social interventions targeting end-of-life care for low-income and minority patients and the well-being of caregivers. Two additional articles address screening considerations in patients at risk for colorectal and lung cancer. Two more articles address safe use of hormone-related therapies to treat symptoms of menopause and prevent disease recurrence or progression in patients diagnosed with noninvasive breast neoplasia. Finally, several articles were included on topics related to COVID-19 vaccination in patients with cancer, use of cannabinoids for cancer pain control, chronic autoimmune adverse effects related to use of immune checkpoint inhibitors, and the incidence of second primary neoplasms.","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":"52 1‐2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140695588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nephrology: What You May Have Missed in 2023. 肾脏病学您可能错过的 2023 年。
Annals of Internal Medicine Pub Date : 2024-04-16 DOI: 10.7326/M24-0605
Ali A M AlHabobi, Ashwaq M S Almutairi, Danah A S Y Bohemid, A. Sehgal
{"title":"Nephrology: What You May Have Missed in 2023.","authors":"Ali A M AlHabobi, Ashwaq M S Almutairi, Danah A S Y Bohemid, A. Sehgal","doi":"10.7326/M24-0605","DOIUrl":"https://doi.org/10.7326/M24-0605","url":null,"abstract":"This article highlights a selection of important nephrology studies published in 2023 that have relevance for nonnephrologist physicians. Four studies examined progression of chronic kidney disease or cardiovascular disease with respect to finerenone use, magnesium supplementation, iron markers, and COVID-19. Two studies examined treatments to improve specific aspects of chronic kidney disease management, including daprodustat to address anemia and patiromer to address hyperphosphatemia. One study showed that acetazolamide added to loop diuretics increased diuresis in acute decompensated heart failure across a wide range of renal function. Another study found that once-daily hydrochlorothiazide did not prevent kidney stone recurrence. Finally, an antibiotic stewardship intervention safely reduced antibiotic prescribing for suspected urinary tract infection in frail older adults.","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":"48 S230","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140694840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书